Rituximab shows long-term efficacy in antibody-associated vasculitis medwireNews medwireNews: A single course of rituximab is a viable alternative to conventional cyclophosphamide/azathioprine immunosuppression in patients with severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, long-term results of the RAVE ... |
